A “Prozone-Like” Effect Influences the Efficacy of the Monoclonal Antibody ABT-700 against the Hepatocyte Growth Factor Receptor

Kedar S. Vaidya,Anatol Oleksijew,Lora A. Tucker,William N. Pappano,Mark G. Anderson,Christine M. Grinnell,Qian Zhang,Sarah J. Heighton,Michael J. Mitten,Sasmita Mishra,Joann P. Palma,Jieyi Wang,Edward B. Reilly,Erwin R. Boghaert

A “Prozone-Like” Effect Influences the Efficacy of the Monoclonal Antibody ABT-700 against the Hepatocyte Growth Factor Receptor

2017

Kedar S. Vaidya
Anatol Oleksijew
Lora A. Tucker
William N. Pappano
Mark G. Anderson
Christine M. Grinnell
Qian Zhang
Sarah J. Heighton
Michael J. Mitten
Sasmita Mishra
Joann P. Palma
Jieyi Wang
Edward B. Reilly
Erwin R. Boghaert

ABT-700 is a therapeutic antibody against the hepatocyte growth factor receptor (MET). At doses or regimens that lead to exposures exceeding optimum in vivo, the efficacy of ABT-700 is unexpectedly re

Keywords:

Antibody
Diabetes mellitus
Chemistry
In vivo
Growth factor receptor inhibitor
Cancer research
Monoclonal antibody
Hepatocyte Growth Factor Receptor
Cisplatin
In vitro
Regimen

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations